Clinical and Molecular Hepatology

KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA): Won-Mook Choi, Ji Won Han, Tae Hyung Kim, Miyoung Choi, Moon Haeng Hur, Hyo Young Lee, Han Ah Lee, Byeong Geun Song, Heechul Nam, Jeong-Ju Yoo, Chang Hun Lee, Gi-Ae Kim, Hye Won Lee, Gwang Hyeon Choi, Young Eun Chon, Yun Bin Lee, Dong Hyun Sinn, Bo Hyun Kim, In Hee Kim, on behalf of the Korean Association for the Study of the Liver (KASL); Received May 9, 2026 Accepted June 2, 2026 Published online June 12, 2026; DOI: https://doi.org/10.3350/cmh.2026.0579 [Epub ahead of print]

PDF

202 View
40 Download

SEVERE HEPATITIS B FLARE AND LIVER FAILURE – CURRENT ASSESSMENT AND MANAGEMENT: Seng Gee Lim, Maria Buti, Jordan J. Feld, James Fung, Adam J. Gehring, K. Rajender Reddy; Received February 4, 2026 Accepted March 11, 2026 Published online March 18, 2026; DOI: https://doi.org/10.3350/cmh.2026.0177 [Accepted]

Abstract
PDF

Hepatitis B flare is a common complication of Chronic Hepatitis B (CHB) and is defined as an increase in HBV viral load associated with abnormal alanine aminotransferases (ALT), the consensus being an ALT≥5xupper limit of normal. The immunopathogenesis is related to induction of inflammatory cells and cytokines by the rise in HBV DNA. There are multiple causes of flares, and they carry the risk of progression to hepatic decompensation and acute-on-chronic liver failure (ACLF) with its associated mortality, potentially requiring liver transplantation. Initial assessment should be exclusion of other causes of liver dysfunction, determine severity, and prognosis. General prognostic models of ACLF are useful but the COSSH-ACLF II score is specific for HBV. Initiation of nucleos(t)ide analogues early is crucial and even in severe HBV flares reduces mortality by 73.6%. Once jaundice and coagulopathy occur, salvage by antivirals is challenging, and such patients should be considered for liver transplantation. However, many patients may not be suitable for transplant or may not have available donor livers as is common in Asia. Recently, there has been increasing evidence of benefit with adjunctive therapies such as corticosteroids and plasma exchange, but this needs to be balanced with the risks and should be considered as rescue therapies in severe HBV flares or ACLF. Liver transplant is the ultimate intervention when these other strategies fail to rescue patients. In summary, HBV flares are clinically serious events that can lead to hepatic decompensation and ACLF but strategies for rescue should be considered before liver transplantation.

920 View
89 Download

Incorporating chronic kidney disease into the cost-effectiveness of MASLD treatment: Eileen L. Yoon, Jeong-Yeon Cho, Mimi Kim, Huiyul Park, Hye-Lin Kim, Dae Won Jun; Received January 20, 2026 Accepted January 24, 2026 Published online February 2, 2026; DOI: https://doi.org/10.3350/cmh.2026.0099 [Accepted]

PDF

806 View
49 Download

Targeting the innate immune system in treating hepatitis B: prospects for functional cure: Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak; Clin Mol Hepatol 2026;32(1):184-199.
Published online November 11, 2025; DOI: https://doi.org/10.3350/cmh.2025.0935

Abstract
PDF

Chronic hepatitis B (CHB) infection remains a significant global public health concern. Functional cure, defined as hepatitis B surface antigen seroclearance with unquantifiable HBV DNA at 24 weeks off treatment, is a desirable endpoint in the treatment of CHB, yet challenging to achieve. Given the limitations of current therapies including nucleos(t)ide analogues and pegylated interferon alpha, novel agents targeting functional cure are emerging. As hepatitis B virus (HBV) is a non-cytolytic virus, liver damage stems from the host immune response towards HBV-infected cells. The innate immune response during the initial phase of HBV infection is crucial in establishing an adequate level of immunity against the virus. However, HBV adopts various mechanisms to evade the host’s innate immunity, partly contributing to the chronicity of infection. This article provides a comprehensive review on how the HBV life cycle interacts with the host’s innate immune system. The latest evidence of novel agents targeting the innate immunity will also be covered. Retinoic acid inducible gene I agonists, toll-like receptor agonists, and interferons are therapies that target the HBV evasion strategies against host’s innate immunity. While small interfering RNAs and antisense oligonucleotides are originally designed for antigen knockdown and reinvigoration of the adaptive immune response, they have also shown additional impacts on the innate immunity. With ongoing research and innovation in combination strategies, advancement in the management of CHB is anticipated in the future.

Citations

Citations to this article as recorded by

Current Status and Prospects of Clinical Research on Low-Level Viremia in Chronic Hepatitis B after Treatment
颜刘
Advances in Clinical Medicine.2026; 16(03): 1942. CrossRef

2,958 View
252 Download
Crossref

Rethinking ACLF Prognosis: Can Machine Learning Outperform Conventional Scores? Editorial on: Predictive Machine Learning Model in ICU Patients with Acute-on-Chronic Liver Failure and Two or More Organ Failures: Jung Hee Kim; Received September 15, 2025 Accepted September 17, 2025 Published online September 23, 2025; DOI: https://doi.org/10.3350/cmh.2025.1053 [Accepted]

PDF

1,168 View
68 Download

Human cytomegalovirus reactivation in decompensated cirrhosis: marker of immunosuppression or contributor to severity?: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”: Zhujun Cao, Richard Moreau; Clin Mol Hepatol 2026;32(2):953-956.
Published online September 1, 2025; DOI: https://doi.org/10.3350/cmh.2025.0962

PDF

2,799 View
46 Download

Reply to Letter on “Sex-Specific Trends and Demographic vs Epidemiologic Drivers of Alcohol-Related Cirrhosis in the U.S., 2021–2040”: Pojsakorn Danpanichkul, Luis Antonio Diaz, Juan Pablo Arab, Amit G. Singal, Ju Dong Yang; Received August 24, 2025 Accepted August 29, 2025 Published online September 1, 2025; DOI: https://doi.org/10.3350/cmh.2025.0948 [Accepted]

PDF

2,373 View
16 Download

Letter to the editor on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease”: Prajnasini Satapathy, Rachana Mehta, Ranjana Sah; Clin Mol Hepatol 2026;32(2):e139-e140.
Published online August 8, 2025; DOI: https://doi.org/10.3350/cmh.2025.0875

PDF

3,356 View
32 Download

Breaking the chain of perinatal hepatitis B transmission: Editorial on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program”: Shang-Chin Huang, Jia-Horng Kao; Clin Mol Hepatol 2026;32(2):946-948.
Published online July 28, 2025; DOI: https://doi.org/10.3350/cmh.2025.0801

PDF

2,196 View
24 Download

Global strategies and actions to eliminate hepatitis B virus infection: Chih-Lin Lin, Jia-Horng Kao; Clin Mol Hepatol 2025;31(4):1197-1212.
Published online July 28, 2025; DOI: https://doi.org/10.3350/cmh.2025.0492

Abstract
PDF

Through the implementation of hepatitis B vaccination and effective antiviral treatment over the past four decades, the hepatitis B surface antigen (HBsAg) seroprevalence of the vaccinated generation dramatically decline. The incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) also decreases. However, the elimination of HBV is still a challenge to achieve. Novel HBV biomarkers, including quantitative HBsAg, hepatitis B virus core-related antigen and HBV RNA are promising in predicting clinical phases, risks of disease progression and HBV functional cure. Current antiviral therapies, nucleoside/nucleotide and pegylated alpha-interferon, effectively decrease HCC incidence in chronic hepatitis B (CHB) patients and minimize the recurrence of HCC in patients receiving curative therapy. Novel agents under development to achieve HBV cure include direct-acting antivirals that target various stages of the HBV lifecycle and host targeting agents that enhance HBV-specific immunity. The action plans for eliminating hepatitis B in the future are universal HBV screening, early and simplified treatment as well as precision lifelong management for CHB patients. This narrative review will summarize and discuss global strategies and initiatives aimed at eliminating HBV infection.

Citations

Citations to this article as recorded by

Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches
Prashant Tiwari, Istuti Saraswat, Jyoti Gupta
Current Microbiology.2026;[Epub] CrossRef
Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification
Tai-Chung Tseng, Shang-Chin Huang, Jia-Horng Kao
Hepatology Communications.2026;[Epub] CrossRef
Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications
Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G. Duda, Ao Huang, Jian Zhou
Portal Hypertension & Cirrhosis.2026; 5(1): 65. CrossRef
Exploration and optimization of indole derivatives as novel anti-HBV agent with potential TLR7-agonistic effect
Lihua Yang, Zibin Qiu, Xincheng Li, Jiachen Wei, Yike Ma, Weiqun Yuan, Qiuting Xu, Xiaoke Gu, Jingying Qiu
Bioorganic & Medicinal Chemistry.2026; 138: 118662. CrossRef
Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks
Kui Wang, Ruchen Zhou
Clinical and Molecular Hepatology.2026; 32(2): e211. CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef

7,026 View
264 Download
5 Web of Science
Crossref

Reconsidering the role of plasma pgRNA in NUC-treated CHB: Stratified biomarker interpretation and the limits of current assays: Letter to the editor on “Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters”: Xu Han, Jun Sun, Yinyan Li; Clin Mol Hepatol 2026;32(2):e131-e133.
Published online July 9, 2025; DOI: https://doi.org/10.3350/cmh.2025.0642

PDF

2,050 View
40 Download

Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation: Changze Hong, Zuxiong Huang, Yingli He, Rongqi Wang, Jiaying Lin, Yushan Liu, Baicheng Liu, Xiaoqin Lan, Qinjun He, Wenfan Luo, Qintao Lai, Ling Zhou, Tingting Qi, Yali Ji, Miaoxia Liu, Qiaoping Wu, Yichen Yao, Weihao Liang, Xianbo Wang, Guohong Deng, Yanhang Gao, Yan Huang, Feng Liu, Xiaobo Lu, Zhongji Meng, Yuemin Nan, Hai Li, Beiling Li, Rajiv Jalan, Jinjun Chen; Clin Mol Hepatol 2025;31(4):1316-1332.
Published online July 4, 2025; DOI: https://doi.org/10.3350/cmh.2025.0332

Background/Aims
The role of reactivation of human cytomegalovirus (HCMV) in determining outcomes of cirrhotic patients with acute decompensation (AD) is unknown. We aimed to investigate HCMV incidence and potential correlation with hepatic outcomes in AD patients.
Methods
Two prospective multicentre cohorts with AD patients were investigated. Patients in cohort 1 were recruited from 4 centres, while patients in cohort 2 were randomly selected from a second multicentre cohort. HCMV reactivation was established with quantitative real-time polymerase chain reaction assay in seropositive patients.
Results
HCMV reactivation was found in 35 patients from cohort 1 (n=722) and 14 from cohort 2 (n=291), with an incidence of 4.8% in both cohorts. Bacterial infection and liver failure were independently correlated with HCMV reactivation. HCMV reactivation was an independent predictor of 90-day mortality. Among bacterial infection populations in these two cohorts, patients with HCMV reactivation had worse prognosis compared to those without. Incidence of acute-on-chronic liver failure (ACLF) was higher in patients with HCMV reactivation compared to those without and was also independently correlated with development of ACLF. In a total of 49 HCMV reactivation cases, 8 patients were treated with ganciclovir, in whom a significantly lower 90-day mortality compared with those not treated was observed. All 3 patients who underwent liver transplantation with reactivation of HCMV died.
Conclusions
In AD patients, HCMV reactivation was common, especially in those with bacterial infection or liver failure, and they were more prone to having ACLF and 90‑day mortality. The data propose the need for active surveillance for HCMV infection in AD patients.

Citations

Citations to this article as recorded by

Human cytomegalovirus reactivation in decompensated cirrhosis: marker of immunosuppression or contributor to severity?: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
Zhujun Cao, Richard Moreau
Clinical and Molecular Hepatology.2026; 32(2): 953. CrossRef
Correspondence to editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
Changze Hong, Jinjun Chen
Clinical and Molecular Hepatology.2026; 32(2): e227. CrossRef
Call for preemptive treatment of cytomegalovirus in patients with cirrhosis and acute decompensation: Editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation”
Norihiro Imai
Clinical and Molecular Hepatology.2026; 32(2): 949. CrossRef

4,988 View
150 Download
3 Web of Science
Crossref

Correspondence to letter to the editor on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States”: Pojsakorn Danpanichkul, Luis Antonio Diaz, Juan Pablo Arab, Amit G. Singal, Ju Dong Yang; Clin Mol Hepatol 2026;32(2):e246-e248.
Published online June 17, 2025; DOI: https://doi.org/10.3350/cmh.2025.0594

PDF

Citations

Citations to this article as recorded by

Reply to correspondence 2 on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States”
Dibin Liu
Clinical and Molecular Hepatology.2026; 32(2): e264. CrossRef
Sex chromosomes/hormones and the tumor microenvironment of non-reproductive cancers
Chun-Miao Zhang, Zhong-Bo Ge, Hai-Hong Zhou, Meng-Xiao Wei, Xin-Yuan Ding, Zhe-Zheng Lin, Ming-Yu Wang, Cai-Juan Bai
Frontiers in Immunology.2025;[Epub] CrossRef
Rising burden of steatotic liver disease in women of childbearing age and projections till 2035
Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang
JHEP Reports.2025; : 101646. CrossRef
Stable Nationwide Sepsis-Related Mortality Does Not Extend to Individuals with Alcohol-Associated Liver Disease
Pojsakorn Danpanichkul, Kwanjit Duangsonk, Claire S. Faulkner, Supapitch Sirimangklanurak, Tulaton Sodsri, Natchaya Polpichai, Shu-Yen Chan, Yanfang Pang, Omar Y. Mousa, Donghee Kim, Suthat Liangpunsakul, Karn Wijarnpreecha
Digestive Diseases and Sciences.2025;[Epub] CrossRef

3,026 View
34 Download
Crossref

Reply to correspondence on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”: Heejoon Jang, Won Kim; Clin Mol Hepatol 2026;32(2):e254-e256.
Published online June 9, 2025; DOI: https://doi.org/10.3350/cmh.2025.0533

PDF

2,757 View
30 Download

Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer: Correspondence to the editorial on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States”: Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang; Clin Mol Hepatol 2026;32(1):e96-e98.
Published online May 15, 2025; DOI: https://doi.org/10.3350/cmh.2025.0527

PDF

Citations

Citations to this article as recorded by

Reply to correspondence 1 on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States”
Sung-Eun Kim
Clinical and Molecular Hepatology.2026; 32(1): e125. CrossRef

5,072 View
25 Download
Crossref

Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”: Shang-Chin Huang, Jia-Horng Kao; Clin Mol Hepatol 2026;32(1):e117-e118.
Published online May 13, 2025; DOI: https://doi.org/10.3350/cmh.2025.0500

PDF

4,238 View
29 Download

Correspondence to editorial 1 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”: Rui Huang, Mindie H. Nguyen; Clin Mol Hepatol 2026;32(1):e83-e84.
Published online May 8, 2025; DOI: https://doi.org/10.3350/cmh.2025.0479

PDF

Citations

Citations to this article as recorded by

Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”
Shang-Chin Huang, Jia-Horng Kao
Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef

3,595 View
15 Download
Crossref

Correspondence to editorial 2 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”: Rui Huang, Mindie H. Nguyen; Clin Mol Hepatol 2026;32(1):e85-e86.
Published online May 8, 2025; DOI: https://doi.org/10.3350/cmh.2025.0478

PDF

Citations

Citations to this article as recorded by

Reply to correspondence on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Heejoon Jang, Won Kim
Clinical and Molecular Hepatology.2026; 32(2): e254. CrossRef

2,807 View
18 Download
Crossref

Non-infectivity of hepatitis B virus under nucleoside analog therapy revealed through auxiliary partial orthotopic liver transplantation: Xiaojie Chen, Guiwen Guan, Lin Wei, Jidong Jia, Xiangmei Chen, Fengmin Lu, Zhijun Zhu; Clin Mol Hepatol 2025;31(3):e263-e267.
Published online May 8, 2025; DOI: https://doi.org/10.3350/cmh.2025.0393

9,113 View
82 Download

Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”: Heejoon Jang, Won Kim; Clin Mol Hepatol 2026;32(1):426-428.
Published online April 28, 2025; DOI: https://doi.org/10.3350/cmh.2025.0430

PDF

Citations

Citations to this article as recorded by

Correspondence to editorial 2 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Rui Huang, Mindie H. Nguyen
Clinical and Molecular Hepatology.2026; 32(1): e85. CrossRef

3,572 View
56 Download
1 Web of Science
Crossref

Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”: Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang; Clin Mol Hepatol 2026;32(1):e55-e57.
Published online April 15, 2025; DOI: https://doi.org/10.3350/cmh.2025.0379

PDF

4,533 View
44 Download

Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”: Shang-Chin Huang, Jia-Horng Kao; Clin Mol Hepatol 2026;32(1):423-425.
Published online April 11, 2025; DOI: https://doi.org/10.3350/cmh.2025.0369

PDF

Citations

Citations to this article as recorded by

Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”
Shang-Chin Huang, Jia-Horng Kao
Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef
Correspondence to editorial 1 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Rui Huang, Mindie H. Nguyen
Clinical and Molecular Hepatology.2026; 32(1): e83. CrossRef
Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus
Shang-Chin Huang, Jia-Horng Kao
Biomedical Journal.2026; 49(3): 100969. CrossRef
The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe?
Shang-Chin Huang, Tai-Chung Tseng
Gut and Liver.2026; 20(3): 350. CrossRef
Insulin Resistance and Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients Under Antiviral Therapy
Dong Hyun Sinn, Kyung-Ah Kim, Jung Il Lee, Geum-Youn Gwak
Journal of Korean Medical Science.2026;[Epub] CrossRef

5,138 View
49 Download
2 Web of Science
Crossref

Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States: Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D. Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q. Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G. Singal, Ju Dong Yang; Clin Mol Hepatol 2025;31(3):1058-1070.
Published online April 11, 2025; DOI: https://doi.org/10.3350/cmh.2025.0169

Background/Aims
Harmful alcohol use is a substantial contributor to liver diseases, liver cancer, and extrahepatic neoplasms. Patterns of alcohol consumption have shifted over recent decades. This study evaluates trends in alcohol-associated liver disease (ALD) and alcohol-attributable cancers in the United States (US) from 2000 to 2021.
Methods
Using the methodological framework of the Global Burden of Disease Study 2021, we analyzed trends in incidence, prevalence, and mortality from ALD and alcohol-attributable cancers in the US.
Results
In 2021, there were 28,340 new cases of ALD, 227,730 prevalent cases, and 21,860 deaths attributed to ALD in the US. From 2000 to 2021, ALD incidence, prevalence, and mortality increased by 43%, 36%, and 79%, respectively. The age-standardized incidence and death rate of ALD rose disproportionately among females compared to males. For alcohol-attributable cancers, primary liver cancer, colorectal cancer, and esophageal cancer accounted for the largest share of deaths in 2021. Age-standardized death rates increased significantly for primary liver cancer (annual percent change [APC] 2.21%, 95% confidence interval [CI] 1.70–2.73%) and other pharyngeal cancer (APC 1.35%, 95% CI 1.08–1.62%).
Conclusions
The burden of ALD is substantial and continues to rise in the US, with a particularly notable increase among females. Mortality from alcohol-attributable cancers is also increasing, mainly driven by primary liver cancer and pharyngeal cancer. However, system-wise, gastrointestinal cancer had the highest death attributable to alcohol. These findings highlight the urgent need for public health strategies to tackle ALD, primary liver cancer, and alcoholattributable extrahepatic malignancies.

Citations

Citations to this article as recorded by

Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer: Correspondence to the editorial on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the Unite
Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
Clinical and Molecular Hepatology.2026; 32(1): e96. CrossRef
Rising burden of steatotic liver disease in women of childbearing age and projections to 2035
Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang
JHEP Reports.2026; 8(1): 101646. CrossRef
Improved survival and reduced alcohol‐associated hepatitis risk with renin‐angiotensin‐aldosterone system inhibitors in alcohol‐associated liver disease
Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Andrew F. Ibrahim, Primrose Tothanarungroj, Omar Al Ta'ani, Narathorn Kulthamrongsri, Kwanjit Duangsonk, Robert J. Wong, Daniel Q. Huang, Karn Wijarnpreecha, Mazen Noureddin, Suthat Liangpunsakul
Alcohol, Clinical and Experimental Research.2026;[Epub] CrossRef
Spatiotemporal trends, demographic disparities, and predictions to 2040 in gastrointestinal cancer mortality in the United States
Maolang He, Jingyi Zhang, Shangqi Wang, Kainan Xing, Yanxin Zhao, Jianzhen Chen, Xi Zhang, Yong Zheng, Shuxin Tian
BMC Public Health.2026;[Epub] CrossRef
Global burden of esophageal cancer attributable to smoking and alcohol, 1990–2021, with projections to 2040: a population-based analysis of the global burden of disease study 2021
Hui Zhou, Jiao Wu, Yuan Yin
Annals of Medicine.2026;[Epub] CrossRef
The global epidemiology of alcohol-associated liver disease
Pojsakorn Danpanichkul, Francisco Idalsoaga, Frank Murray, Juan Pablo Arab, Luis Antonio Díaz
Hepatology Communications.2026;[Epub] CrossRef
MetALD: new insights and unraveling therapeutic potential
Yue Feng, PanShiLi Han, Tao Liu, YanHang Gao
Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Sex Disparity in Major Adverse Liver Outcome and Major Adverse Cardiac Event in Alcohol‐Associated Liver Disease
Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Mark D. Muthiah, Suthat Liangpunsakul
Liver International.2025;[Epub] CrossRef
Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis
Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul
Alcohol, Clinical and Experimental Research.2025; 49(11): 2451. CrossRef
Consumo de alcohol y cirrosis en mujeres: un riesgo subestimado
P. Huerta, J.P. Arab, L.A. Díaz
Revista de Gastroenterología de México.2025; 90(4): 509. CrossRef
Alcohol use and cirrhosis in women: An underestimated risk
P. Huerta, J.P. Arab, L.A. Díaz
Revista de Gastroenterología de México (English Edition).2025; 90(4): 509. CrossRef
Etiology of cirrhosis is associated with risk of hepatic decompensation and hepatocellular carcinoma
Michelle Ng, Olgert Bardhi, Krystal Lai, Eden Koo, Sruthi Yekkaluri, Kevin Bass, Guruveer Bhamra, Pojsakorn Danpanichkul, Lisa Quirk, Ju Dong Yang, Jeremy Louissaint, Thomas A. Kerr, Amit G. Singal
BMC Gastroenterology.2025;[Epub] CrossRef
Stable Nationwide Sepsis-Related Mortality Does Not Extend to Individuals with Alcohol-Associated Liver Disease
Pojsakorn Danpanichkul, Kwanjit Duangsonk, Claire S. Faulkner, Supapitch Sirimangklanurak, Tulaton Sodsri, Natchaya Polpichai, Shu-Yen Chan, Yanfang Pang, Omar Y. Mousa, Donghee Kim, Suthat Liangpunsakul, Karn Wijarnpreecha
Digestive Diseases and Sciences.2025;[Epub] CrossRef

13,614 View
169 Download
21 Web of Science
Crossref

Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrum: Vishnu Girish, Rakhi Maiwall; Clin Mol Hepatol 2025;31(3):730-752.
Published online March 26, 2025; DOI: https://doi.org/10.3350/cmh.2024.1060

Abstract
PDF

Kidney disease in cirrhosis is now viewed as a continuum encompassing acute kidney injury (AKI), acute kidney disease (AKD), and chronic kidney disease (CKD), rather than three different disorders. Contemporary diagnostic criteria for AKI integrate urine output (UO) parameters and acknowledge the intricate relationship and possibility of overlap between functional and structural as well as acute and chronic entities, including hepatorenal syndrome (HRS). AKI demonstrates a propensity for progression to AKD and CKD, particularly in the context of recurrent and severe insults. The diagnostic complexity is further compounded by limitations in serum creatinine measurements, prompting the integration of novel biomarkers and the need to accurately estimate glomerular filtration rate. The diagnosis, phenotyping, and management of AKI should be prompt and early; the initial step should always be volume and UO assessment. A personalized approach is needed and the possibility of co-existing structural or functional kidney disease should be borne in mind. The earlier concept of waiting for 48 hours to diagnose HRS has evolved and early diagnosis and prompt treatment are advised now. Kidney replacement therapy and simultaneous liver and kidney transplantation may be required in resistant cases.

Citations

Citations to this article as recorded by

Comprehensive Conservative Management Versus Dialysis in Uric Acid Control
Francesca K. Martino, Greta Redi, Marco Bogo, Elena Sgrò, Alessandra Zattarin, Giovanni Samassa, Lucia Federica Stefanelli, Anna Basso, Federico Nalesso
Dietetics.2026; 5(1): 9. CrossRef
Renal Recovery Benefit of Living Versus Deceased Donor Liver Transplantation in Recipients With High Model for End-stage Liver Disease Scores: A Propensity Score-matched Study
Sung-Min Kim, Rak-Kyun Oh, Young-In Yoon, Won-Mook Choi, Shin Hwang, Ki-Hun Kim, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Sung-Gyu Lee
Transplantation.2026; 110(5): e1016. CrossRef
Early prediction of acute kidney injury after therapeutic paracentesis in decompensated liver cirrhosis: diagnostic value of IL-18, KIM-1, and FGF-23
Ahmed Fayed, Ahmed Ramadan, Tarek Ramzy, Amr Shaker
Renal Failure.2026;[Epub] CrossRef
Risk factors for acute kidney injury in pediatric intensive care units: a systematic review and meta-analysis
Rong Li, Qianqian Yang
BMC Pediatrics.2026;[Epub] CrossRef
Molecular Biomarkers and Risk Prediction Models for Acute Kidney Injury Following Liver Transplantation: A Review
Bing Bin, Yuxiao Chen, Shijian Li, Jihua Wu
Journal of Clinical and Experimental Hepatology.2026; 16(4): 103550. CrossRef
Demographic and regional trends of mortality associated with hepatic cirrhosis and chronic kidney disease, in the United States, 1999-2020: A CDC WONDER database analysis
Mateen Ahmad, Ayman Irshad, Sahaab Noor, Humna Irshad, Muhammad Aliyan Ahmed
Journal of the National Medical Association.2026; 118(3): 525. CrossRef
Uncovering immune dysfunction in ACLF: cellular mechanisms, molecular pathways, and therapeutic frontiers.
Marti Ortega-Ribera, Robert Brenig, Christine Bernsmeier, Gyongyi Szabo
Journal of Hepatology.2026;[Epub] CrossRef
Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective
Florence Wong, Danielle Adebayo, Jacob George, Ramazan Idilman, Peter C Hayes, Mario R Alvares-da-Silva, Aldo Torre, Hailemichael Desalgn Mekonnen, Wai-Kay Seto, Shiv Kumar Sarin, Zhujun Cao, Neil Rajoriya, Aabha Nagral, Henok Fisseha, Anand V Kulkarni, C
Gut.2026; : gutjnl-2025-336802. CrossRef
Association between the C-reactive protein–triglyceride–glucose index (CTI) and the risk of acute kidney injury in critically ill patients with cirrhosis
Lu-Huai Feng, Tianbao Liao, Tingting Su, Xuefei Zhou, Yang Lu, Lina Huang, Zhenhua Yang
BMC Nephrology.2025;[Epub] CrossRef

11,254 View
264 Download
6 Web of Science
Crossref

Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues: Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Atsukawa, Hirokazu Takahashi, Kunihiko Tsuji, Koichi Takaguchi, Pei-Chien Tsai, Chia-Yen Dai, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Eileen Yoon, Sung Eun Kim, Sang Bong Ahn, Gi-Ae Kim, Jang Han Jung, Soung Won Jeong, Hyunwoo Oh, Cheng-Hao Tseng, Masatoshi Ishigami, Angela Chau, Mayumi Maeda, Satoshi Yasuda, Makoto Chuma, Takanori Ito, Keigo Kawashima, Joanne Kimiko Liu, Adrian Gadano, Ritsuzo Kozuka, Norio Itokawa, Kaori Inoue, Tomonori Senoh, Jie Li, Wan-Long Chuang, Ramsey Cheung, Chao Wu, Ming-Lung Yu, Mindie H. Nguyen; Clin Mol Hepatol 2025;31(3):1003-1017.
Published online March 17, 2025; DOI: https://doi.org/10.3350/cmh.2024.1070

Background/Aims
Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment.
Methods
We analyzed data from CHB patients for whom initiated NA treatment from 30 centers. We balanced patient characteristics with and without metabolic disease (diabetes, obesity, dyslipidemia, and hypertension) via propensity-score matching (PSM) to evaluate adverse outcomes.
Results
The study included 4,500 patients. PSM yielded 909 pairs of patients with balanced characteristics. When stratified by the number of metabolic diseases, only patients with ≥2 metabolic diseases had an increased cumulative incidence of cirrhosis and overall death. However, when stratified by the presence of diabetes (regardless of the presence or number of other metabolic diseases), patients with diabetes (versus those without) had a significantly higher cumulative incidence of all outcomes: cirrhosis (P=0.009), hepatocellular carcinoma (HCC, P=0.023), and overall, liver-related, and non-liver-related death (P<0.001, P=0.026 and P<0.001, respectively). Having ≥2 metabolic diseases was associated with cirrhosis, overall death, and non-liver-related death but not HCC or liver-related death, while diabetes was significantly associated with a higher risk of all outcomes: cirrhosis (hazard ratio [HR]=3.75, P=0.004), HCC (HR=2.02, P=0.020), and overall, liver-related, and non-liver-related death (HR=2.53, P<0.001; HR=2.65, P=0.016; HR=2.38, P<0.001).
Conclusions
Having two or more metabolic diseases was associated with a higher risk of cirrhosis, overall death, and non-liver-related death, but having diabetes as a single metabolic disease was significantly associated with all adverse outcomes including cirrhosis, HCC, and overall, liver-related, and non-liver-related death.

Citations

Citations to this article as recorded by

Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis
Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut
Hepatology.2026; 83(5): 1273. CrossRef
Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”
Shang-Chin Huang, Jia-Horng Kao
Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Shang-Chin Huang, Jia-Horng Kao
Clinical and Molecular Hepatology.2026; 32(1): 423. CrossRef
Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection
Talal K Bhatti, Joseph K Lim
World Journal of Gastroenterology.2026;[Epub] CrossRef
Diabetes Impairs the Virological Response in Patients with Chronic Hepatitis B: Glycemic Control as a Key Modifiable Risk Factor
Aoyi Li, Yan Han, Guanglin Xiao, Zhiling Deng, Chaojing Wen, Ke Qiu, Taiyu He, Hong Ren
Journal of Clinical Medicine.2026; 15(5): 1826. CrossRef
Antiviral Therapy Reduces Hepatocellular Carcinoma and Cirrhosis Risk in Chinese Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase
Jian Wang, Zhiyi Zhang, Li Zhu, Tao Fan, Ye Xiong, Shaoqiu Zhang, Chao Jiang, Shengxia Yin, Xin Tong, Juan Xia, Xiaomin Yan, Renling Yao, Yu Shi, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang
Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus
Shang-Chin Huang, Jia-Horng Kao
Biomedical Journal.2026; 49(3): 100969. CrossRef
Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver‐Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy
Chung‐Feng Huang, Yi‐Hung Lin, Pei‐Chien Tsai, Ming‐Lun Yeh, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yu‐Ju Wei, Nai‐Jen Hou, Ming‐Yen Hsieh, Chao‐Kuan Huang, Tzu‐Chun Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B
Hung-Wei Wang, Hsueh-Chou Lai, Wei-Fan Hsu, Sheng-Hung Chen, Yi-Chun Kuo, Cheng-Yuan Peng
Annals of Medicine.2026;[Epub] CrossRef
Diagnosing and defining MASLD in people living with chronic hepatitis B
Emily Martyn, Alejandro Arenas-Pinto, Richard Gilson, Nomathemba Chandiwana, Stuart Flanagan, Douglas MacDonald, Emmanuel A. Tsochatzis, W. D. Francois Venter, Jennifer Manne-Goehler, Philippa C. Matthews
Communications Medicine.2026;[Epub] CrossRef
The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe?
Shang-Chin Huang, Tai-Chung Tseng
Gut and Liver.2026; 20(3): 350. CrossRef
Differential HCC risk among HBV indeterminate types at baseline and by phase transition
Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris
Gut.2025; 74(11): 1873. CrossRef
Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment
Jian Wang, Tao Fan, Zhiyi Zhang, Li Zhu, Shaoqiu Zhang, Ye Xiong, Chun Shan, Chao Jiang, Shengxia Yin, Xin Tong, Renling Yao, Juan Xia, Xiaomin Yan, Yu Shi, Yuxin Chen, Xingxiang Liu, Huali Wang, Haixia Zhang, Chuanwu Zhu, Qun Zhang, Chao Wu, Rui Huang
Emerging Microbes & Infections.2025;[Epub] CrossRef
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study
Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats
eClinicalMedicine.2025; 87: 103407. CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Multifunctional Metal Composite Hydrogels for Diabetic Wound Therapy
Shengnan Zhang, Hui Gao, Kevin H. Mayo, Jingang Mo, Le Deng
Gels.2025; 11(12): 960. CrossRef

14,219 View
251 Download
20 Web of Science
Crossref

Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Correspondence to editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”: Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming-Lung Yu; Clin Mol Hepatol 2026;32(1):e68-e71.
Published online March 4, 2025; DOI: https://doi.org/10.3350/cmh.2025.0235

PDF

Citations

Citations to this article as recorded by

Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients: Correspondence to letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu
Clinical and Molecular Hepatology.2026; 32(1): e99. CrossRef
Should direct-acting antiviral be considered for all patients with HCV-related hepatocellular carcinoma?: Reply to correspondence on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
Yan Ling Ong, Apichat Kaewdech, Yu Jun Wong
Clinical and Molecular Hepatology.2026; 32(1): e109. CrossRef
The Clinical Use of Stem Cells in Liver Cancer Treatment: Interactions Between Diet, Metabolic Disease and Hepatic Regeneration
Julia Coelho Moura, Vincent S Gallicchio
Journal of Regenerative Medicine and Biology Research.2026; 7(2): 1. CrossRef

5,438 View
45 Download
1 Web of Science
Crossref

Liver Transplantation

Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”: Soon Kyu Lee, Jong Young Choi; Clin Mol Hepatol 2025;31(2):e161-e162.
Published online February 13, 2025; DOI: https://doi.org/10.3350/cmh.2025.0121

PDF

6,427 View
38 Download

Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease”: Ho Soo Chun, Minjong Lee; Clin Mol Hepatol 2026;32(1):368-370.
Published online February 11, 2025; DOI: https://doi.org/10.3350/cmh.2025.0116

PDF

6,600 View
50 Download

Liver Transplantation

Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”: Soon Kyu Lee, Jong Young Choi; Clin Mol Hepatol 2025;31(2):e212-e214.
Published online February 10, 2025; DOI: https://doi.org/10.3350/cmh.2025.0100

PDF

6,625 View
26 Download

Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study: Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bair, Te-Sheng Chang, Chun-Yen Lin, Szu-Jen Wang, Tsai-Yuan Hsieh, Tzeng-Hue Yang, Cheng-Yuan Peng, Chi-Chieh Yang, Lee-Won Chong, Chien-Wei Huang, Chih-Wen Lin, Cheng-Hsin Chu, Ming-Chang Tsai, Jia-Horng Kao, Chun-Jen Liu, Wan-Long Chuang, Teng-Yu Lee, Ming-Lung Yu, on behalf of TACR investigators; Clin Mol Hepatol 2025;31(3):899-913.
Published online February 5, 2025; DOI: https://doi.org/10.3350/cmh.2024.1015

Background/Aims
The survival benefit of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection in patients with hepatocellular carcinoma (HCC), particularly in Barcelona Clinic Liver Cancer (BCLC) stages B/C, remains largely uncertain. We aimed to explore the impact of DAA therapy on overall survival (OS) in HCC patients using a nationwide cohort study.
Methods
We utilized the nationwide Taiwan Association for the Study of the Liver (TASL) HCV Registry (TACR) database to include all adults receiving a DAA therapy for HCV, excluding those with other viral infections, liver transplantation, non-HCC malignancies, and terminal-staged HCC. We respectively analyzed the adjusted odds ratio (aOR) for sustained virological response (SVR) and adjusted hazard ratio (aHR) for OS.
Results
Between December 2013 and December 2020, 2,205 (9.3%) patients with HCC and 21,569 (90.7%) patients without HCC were include. The SVR rates were 96.6% in the HCC group and 98.8% in the non-HCC group (P<0.001), with HCC being an independent risk factor affecting SVR (aOR 0.41; 95% CI 0.31–0.54; P<0.001). In the whole patient cohort, SVR was independently associated with improved OS (aHR 0.46; 95% CI 0.35–0.60; P<0.001). Among patients with baseline HCC, SVR remained an independent factor related to OS (aHR 0.41; 95% CI 0.28–0.59; P<0.001). The impact of SVR on OS persisted significantly across BCLC stages 0/A and stages B/C.
Conclusions
High SVR rates among HCC patients underscore the importance of DAA therapy in enhancing OS, reaffirming its efficacy across various HCC stages.

Citations

Citations to this article as recorded by

Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients: Correspondence to letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu
Clinical and Molecular Hepatology.2026; 32(1): e99. CrossRef
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Correspondence to editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming-Lung Yu
Clinical and Molecular Hepatology.2026; 32(1): e68. CrossRef
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bai
European Journal of Cancer.2026; 232: 116109. CrossRef
Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: a nationwide cohort study”
Qiong Wang, Zhongqing Qian, Xiaodi Yang, Deyan Chen, Xiaojing Wang, Fuliang Chen
Clinical and Molecular Hepatology.2026; 32(1): e7. CrossRef
Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC
María Fernanda Guerra‐Veloz, Sital Shah, Beatrice Emmanouil, Mia Olsen, Renita George, Sarah Selemani, Paul J. Ross, Ivana Carey, Neha Mehta, Mark Gillyon‐Powell, Kosh Agarwal
Journal of Viral Hepatitis.2026;[Epub] CrossRef
Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR. Authors' Reply
Yu‐Sheng Lin, Yun‐Yu Chen, Teng‐Yu Lee
Alimentary Pharmacology & Therapeutics.2026; 63(10): 1439. CrossRef
Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
Yu‐Sheng Lin, Hwai‐I Yang, Teng‐Yu Lee
Alimentary Pharmacology & Therapeutics.2026; 63(10): 1429. CrossRef
Letter: Beyond Association—Operationalising PRS‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
Yu‐Sheng Lin, Ying‐Cheng Lin, Teng‐Yu Lee
Alimentary Pharmacology & Therapeutics.2026; 63(10): 1443. CrossRef
HIV, Viral Hepatitis, and Schistosomiasis Association with Liver Cancer: A Systematic Review
Khumbuzile Canham, Pragalathan Naidoo, Sibusiso Senzani, Sayed Shakeel Kader, Zilungile L. Mkhize-Kwitshana
Microorganisms.2025; 13(12): 2753. CrossRef

13,989 View
228 Download
12 Web of Science
Crossref

Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis: Haiyu Wang, Weihao Liang, Ling Zhou, Jiankang Song, Biao Wen, Qiaoping Wu, Yuanjian Zhang, Xiaofeng Zhang, Haoran Ke, Yujun Tang, Fuyuan Zhou, Youfu Zhu, Weiqun Wen, Zhihua Liu, Yali Ji, Qintao Lai, Qinjun He, Wenfan Luo, Tingting Qi, Miaoxia Liu, Xiaoqin Lan, Yongpeng Chen, Ranran Xi, Junting Wan, Lin Dai, Yuan Li, Jinjun Chen; Clin Mol Hepatol 2025;31(3):866-880.
Published online February 5, 2025; DOI: https://doi.org/10.3350/cmh.2024.0609

Background/Aims
Cirrhotic patients with liver stiffness measurement (LSM) <20 kPa and platelet count ≥150×10⁹/L (Baveno VI criteria), otherwise spleen stiffness measurement (SSM) ≤40 kPa (Baveno VI-SSM criteria) can avoid endoscopy screening; however, no prospective data for their hepatic outcomes.
Methods
Compensated cirrhosis with HBV were prospectively enrolled from April 2019 to April 2022 and followed until July 2023. All patients underwent LSM, SSM and esophagogastroduodenoscopy assessment.
Results
Among 1,224 patients enrolled with median follow-up of 30 months (interquartile range, 21–42), the incidence of decompensation was greater in 560 patients with unfavored Baveno VI criteria (0.5 vs. 20.4 per 1,000 person-years, P=0.0004) than that in 664 patients with favored Baveno VI-SSM criteria. The Baveno VI-SSM model identified more patients (54.2%) as low-risk for decompensation than Baveno VII-SSM model (single cutoff) (48.4%, P=0.004) and than Baveno VI criteria (34.6%, P<0.0001) did. Patients with high-risk varices diagnosed via endoscopy following Baveno VI-SSM model assessment had greater probability of decompensation compared to those identified by the Baveno VII-SSM model (single cutoff) (42.8 vs. 21.1 per 1,000 person-years, P=0.0088). Additionally, among the 493 patients who underwent endoscopic re-assessment, 242 patients with favored Baveno VI-SSM criteria had much lower incidence of EV progression (2.6 vs. 99.5 per 1,000 person-years, P=0.0004) and lower risk of decompensation compared to 140 patients with unfavored Baveno VI-SSM model (0 vs. 34.2 per 1,000 person-years, P=0.0256).
Conclusions
Baveno VI-SSM model could identify HBV-related cirrhosis patients at low risk of decompensation, which was greatly improved upon Baveno VI-SSM reassessment.

Citations

Citations to this article as recorded by

Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Haiyu Wang, Jinjun Chen
Clinical and Molecular Hepatology.2026; 32(1): e58. CrossRef
Correspondence to editorial 2 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Haiyu Wang, Jinjun Chen
Clinical and Molecular Hepatology.2026; 32(1): e62. CrossRef
Correspondence to editorial 3 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Haiyu Wang, Jinjun Chen
Clinical and Molecular Hepatology.2026; 32(1): e65. CrossRef
Reply to correspondence on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Mathias Jachs, Mattias Mandorfer
Clinical and Molecular Hepatology.2026; 32(1): e106. CrossRef
Noninvasive Tests for Predicting Decompensation in Compensated Advanced Chronic Liver Disease: A Comprehensive Review
Audrey Payancé, Pierre‐Emmanuel Rautou, Jérôme Boursier, Laurent Castera, Dominique Valla, Laure Elkrief
Liver International.2026;[Epub] CrossRef
Case Report: Systemic amyloidosis unmasked by progressive hepatomegaly after splenectomy for non-traumatic spleen rupture in a patient with chronic liver disease
Li-Ping Sheng, Ya-Yun Zhang, Ming Zhang, Bo-Zhi Lin, Rui-Fang Ma, Li-Na Han, Hui Liu, Feng-Qin Hou, Gui-Qiang Wang
Frontiers in Medicine.2026;[Epub] CrossRef
Ammonia‐to‐Urea Ratio: A Noninvasive First‐Line Tool for Detecting Clinically Significant Portal Hypertension
Hatime Ouahbi, Vincent Haghnejad, Alexia Audouy, Maël Silva Rodriguez, Françoise Barbé, Jean‐Louis Guéant, Jean‐Pierre Bronowicki, Abderrahim Oussalah
JGH Open.2025;[Epub] CrossRef

11,410 View
229 Download
12 Web of Science
Crossref

Liver Transplantation

Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”: Jongman Kim; Clin Mol Hepatol 2025;31(2):589-591.
Published online January 24, 2025; DOI: https://doi.org/10.3350/cmh.2025.0076

PDF

Citations

Citations to this article as recorded by

Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(2): e161. CrossRef

6,775 View
52 Download
1 Web of Science
Crossref

Viral hepatitis

Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0: Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T.F. Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech, Meifang Han, Weiming Yan, Hong Ren, Peng Hu, Sainan Shu, Paul Yien Kwo, Fu-sheng Wang, Man-Fung Yuen, Qin Ning; Clin Mol Hepatol 2025;31(Suppl):S134-S164.
Published online January 22, 2025; DOI: https://doi.org/10.3350/cmh.2024.0780

Abstract
PDF

As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements. The 2.0 Consensus was aimed to update the original consensus with the latest available studies, and provide a comprehensive overview of the current relevant scientific literatures regarding functional cure of hepatitis B, with a particular focus on issues that are not yet fully clarified. These cover the definition of functional cure of hepatitis B, its mechanisms and barriers, the effective strategies and treatment roadmap to achieve this endpoint, in particular new surrogate biomarkers used to measure efficacy or to predict response, and the appropriate approach to pursuing a functional cure in special populations, the development of emerging antivirals and immunomodulators with potential for curing hepatitis B. The statements are primarily intended to offer international guidance for clinicians in their practice to enhance the functional cure rate of chronic hepatitis B.

Citations

Citations to this article as recorded by

Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
Clinical and Molecular Hepatology.2026; 32(1): e55. CrossRef
Dynamics and Sensitivity of the Lifecycle of Hepatitis B Virus
Dmitry Grebennikov, Igor Sazonov, Rostislav Savinkov, Matvey Zakharov, Mark Sorokin, Yakov Mokin, Andreas Meyerhans, Gennady Bocharov
Pathogens.2026; 15(2): 172. CrossRef
ZNF638 represses the transcription of HBV closed circular DNA involving HUSH complex-mediated histone modifications of epigenetic silencing
Sifan Meng, Jiaqian Li, Yunlong Fang, Binwei Duan, Jing Wang, Yang Si, Feng Li, Qiong Wu, Shan Cheng, Wei Ding
Cell Communication and Signaling.2026;[Epub] CrossRef
Response to letters to editor "Next-Step Paradigms for Hepatitis B Functional Cure: Insights from the Anchor Combination Therapy Trial" and “Critical Appraisal of the Anchor RCT on Entecavir, Peginterferon Alfa-2b, and GM-CSF Combination Therapy”
Di Wu, Da Huang, Weiming Yan, Qin Ning
Hepatology International.2026;[Epub] CrossRef
Response to letter to editor—Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon
Jianxia Dong, Sujun Zheng, Xinyue Chen
Hepatology International.2026;[Epub] CrossRef
Mechanisms and management of pegylated interferon-α toxicity in chronic hepatitis B
Liya Zhu, Fei Peng, Dingfang Pi, Jinzhi Lu
Frontiers in Immunology.2026;[Epub] CrossRef
Long-term antiviral therapy sustains HBsAg decline, increases HBV RNA negativity and enhances the proportion of patients achieving functional cure in chronic hepatitis B
Ruihan Gao, Shuting Liu, Shiyu Zhang, Xin Zhou, Bin Zhu, Baoju Wang
Annals of Hepatology.2026; 31(2): 102212. CrossRef
Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks
Kui Wang, Ruchen Zhou
Clinical and Molecular Hepatology.2026; 32(2): e211. CrossRef
A Comparative Study of Entecavir and Tenofovir Alafenamide on Quantitative HBsAg Reduction in Patients With CHB
Jungnam Lee, Young‐Joo Jin
Journal of Medical Virology.2026;[Epub] CrossRef
Hepatitis B in Children: A Review of Current Knowledge and Future Directions
Paola Carolina Espin Diaz, Swati Antala
Current Treatment Options in Pediatrics.2026;[Epub] CrossRef
Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications
Wen Kang, Yu-Shen Liu, Tian-Ping Wang, Shu-Ming Zhang, Yu Li, Ye Zhang
iLIVER.2026; 5(2): 100235. CrossRef
Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controll
Qiran Zhang, Feng Sun, Shulan Sui, Jianmei Lin, Chuncheng Wu, Jing Yuan, Yingli He, Jia Shang, Tao Han, Ying Zhu, Zuxiong Huang, Chen Chen, Chao Qiu, Xing Wang, Jiming Zhang, Yao Xie, Wenhong Zhang
Advances in Therapy.2026;[Epub] CrossRef
Residual viral expression in siRNA-treated HBV-replicating cell and mouse models
Mingzhu Xu, Yuyan Qian, Ziyang Song, Haiyu Wang, Lei Yue, Jiangxia Liu, Yaming Li, Wenjing Zai, Zhenghong Yuan, Jieliang Chen
Antiviral Research.2025; 240: 106210. CrossRef
Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection
Yiwen Shu, Sumeng Li, Yanqin Du, Xin Zheng
Frontiers in Immunology.2025;[Epub] CrossRef
Quantitatively Evaluate the Improvement of Functional Cure for the Quality of Life of Chronic Hepatitis B Cases: Evidence from a Cross-Sectional Study in China
Sihui Zhang, Zhiliang Gao, Hui Li, Yi Kang, Lei Fu, Xuebing Chen, Xiaoyuan Xu, Xinyue Chen, Hui Zhuang, Hui Zheng, Fuqiang Cui
Healthcare.2025; 13(20): 2590. CrossRef
Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study
Yong-Hong Wang, Ya-Chao Tao, Meng-Lan Wang, Cheng-Run Song, Jiang-Nan Peng, En-Qiang Chen
Journal of Virus Eradication.2025; 11(4): 100617. CrossRef
An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection
Ze-Ao Huang, Yang Yang, Shuo Yang, Guang-Shen Ji, Rui Fu, Zhi-Kang Tian, Yu-Cheng Wu, Geng-Shen Song
Nature Communications.2025;[Epub] CrossRef
A Study on Serum Protein Tracking in Patients with Low Levels of HBsAg Undergoing Treatment for Chronic Hepatitis B with a Combination of Tenofovir Disoproxil Fumarate and Pegylated Interferon
Yimin Chen, Min Deng, Mingkai Tong, Peixia Lin, Hua Xuan, Dahai Wei
Hepatitis Monthly.2025;[Epub] CrossRef
Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study
Jianxia Dong, Shan Ren, Jing Zhao, Pengxuan Wu, Haitian Yu, Yao Xie, Junliang Fu, Xiaorong Mao, Zhiliang Gao, Bingliang Lin, Qingfa Ruan, Yongfang Jiang, Xiulan Xue, Yueyong Zhu, Haidong Zhao, Haifang Cao, Xinyue Chen, Sujun Zheng
Virology Journal.2025;[Epub] CrossRef
Functional cure of chronic hepatitis B virus infection: current therapeutic regimens
Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao
Hepatoma Research.2025;[Epub] CrossRef

19,092 View
674 Download
20 Web of Science
Crossref

Liver Transplantation

Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”: Rui Shi, Minghua Wang; Clin Mol Hepatol 2025;31(2):e137-e139.
Published online January 9, 2025; DOI: https://doi.org/10.3350/cmh.2024.1159

PDF

Citations

Citations to this article as recorded by

Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(2): e212. CrossRef

7,185 View
48 Download
1 Web of Science
Crossref

Viral hepatitis

Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”: Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin; Clin Mol Hepatol 2025;31(2):e169-e172.
Published online December 23, 2024; DOI: https://doi.org/10.3350/cmh.2024.1138

PDF

6,430 View
37 Download

Viral hepatitis

Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”: Jian Wang, Fei Cao, Chuanwu Zhu, Chao Wu, Rui Huang; Clin Mol Hepatol 2025;31(2):e140-e142.
Published online December 3, 2024; DOI: https://doi.org/10.3350/cmh.2024.0960

Citations

Citations to this article as recorded by

Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TOR
Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin
Clinical and Molecular Hepatology.2025; 31(2): e169. CrossRef

7,048 View
37 Download
1 Web of Science
Crossref

Viral hepatitis

Prospect of emerging treatments for hepatitis B virus functional cure: Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen; Clin Mol Hepatol 2025;31(Suppl):S165-181.
Published online November 14, 2024; DOI: https://doi.org/10.3350/cmh.2024.0855

Abstract
PDF

Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) seroclearance with unquantifiable hepatitis B virus (HBV) DNA at 24 weeks off treatment, is a favorable treatment endpoint in chronic hepatitis B (CHB). Nonetheless, functional cure is rarely attained with the current treatment modalities of nucleos(t)ide analogues (NUCs) and pegylated interferon alpha. Multiple novel virus-targeting agents and immunomodulators are under development for HBV with functional cure as the treatment goal. Among virus-targeting agents, antisense oligonucleotides and small-interfering RNAs are the most advanced in the developmental pipeline, and can induce potent and sustainable HBsAg suppression. The other virus-targeting agents have varying effects on HBsAg and HBV DNA, depending on the drug mechanism. In contrast, immunomodulators have modest effects on HBsAg and have limited roles in monotherapy. Multiple combination regimens incorporating RNA interference agents with immunomodulators have been studied through many ongoing clinical trials. These combination strategies demonstrate synergistic effects in inducing functional cure, and will likely be the future direction of development. Despite the promising results, research is warranted to optimize treatment protocols and to establish criteria for NUC withdrawal after novel therapies. Functional cure is now an attainable target in CHB, and the emerging novel therapeutics will revolutionize CHB management.

Citations

Citations to this article as recorded by

Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure
Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen
Gut.2026; 75(1): 119. CrossRef
Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
Clinical and Molecular Hepatology.2026; 32(1): e55. CrossRef
Viral manipulation of host cell glutamine metabolism and glutamine rewiring in hepatic diseases: Editorial on “Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalentl
Mehrangiz Dezhbord, Kyun-Hwan Kim
Clinical and Molecular Hepatology.2026; 32(1): 385. CrossRef
Targeting the innate immune system in treating hepatitis B: prospects for functional cure
Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
Clinical and Molecular Hepatology.2026; 32(1): 184. CrossRef
Large-scale screening of HBV epitopes restricted by multiple prevalent HLA-B/C allotypes and routine detection of HBV-specific T cells in CHB patients
Yandan Wu, Yu Zhao, Ruixue Ji, Pinqing Li, Huijuan Chen, Fangping Yue, Yi Wu, Jie Qiu, Chuanlai Shen
Frontiers in Immunology.2026;[Epub] CrossRef
Group-based trajectory modeling for declines in hepatitis B surface antigen over time accurately identifies chronic hepatitis B patients achieving functional cure: a single-center cohort study in China
Yuchen Peng, Liping Liu, Xiaoping Wu
Annals of Medicine.2026;[Epub] CrossRef
Risk Prediction of Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance in Patients With Chronic Hepatitis B
Shuaibing Ying, Jinyao Dai, Qiudan Zhang, Yujing Wang, Yina Yu, Zhijuan Zhang, Shaohua Dong, Yichun Zhang, Haoyang Hu, Yuqi Hong, Yi Liu, Yuqi Guo, Haomin Yan, Yunqing Qiu, Yan Lou
Alimentary Pharmacology & Therapeutics.2026;[Epub] CrossRef
Sodium taurocholate cotransporting polypeptide in HBV-related diseases: from underlying mechanisms to targeted therapies
Qiang Xie, Qingbo Liu, Xin Zheng, Leilei Fu, Hussein H. Aly, Bo Liu
Drug Discovery Today.2026; 31(3): 104664. CrossRef
Exploration and optimization of indole derivatives as novel anti-HBV agent with potential TLR7-agonistic effect
Lihua Yang, Zibin Qiu, Xincheng Li, Jiachen Wei, Yike Ma, Weiqun Yuan, Qiuting Xu, Xiaoke Gu, Jingying Qiu
Bioorganic & Medicinal Chemistry.2026; 138: 118662. CrossRef
CD16+ γδ T cells mediate antibody-dependent cellular cytotoxicity and associate with viral control in chronic hepatitis B virus infection
Paulina E Schröter, Katja Steppich, Laura Fernández Carrera, Zheng Song, Sebastian Klein, Roni Souleiman, Melanie Urbanek-Quaing, Ayesha D Lietzau, Ansgar Schnieders, Erich Freyer, Birgit Bremer, Ximena León-Lara, Vicente Almeida, Rodrigo Gutierrez Jaureg
Gut.2026; : gutjnl-2025-337640. CrossRef
Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic Frontiers
Liping Xu, Huaqun Zhang, Bingchen Jiang, Yuanying Jiang, Hui Lu
Pharmaceutics.2026; 18(4): 446. CrossRef
Repurposing Product Nkabinde for Hepatitis B Virus Therapy: A Network Pharmacology and Molecular Docking Investigation
Samuel Chima Ugbaja, Siphathimandla Authority Nkabinde, Magugu Nkabinde, Nceba Gqaleni
Pharmaceuticals.2026; 19(4): 627. CrossRef
Reply to: “ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFNα based therapy”
Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
Journal of Hepatology.2025; 82(5): e228. CrossRef
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?
Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
Hepatology International.2025; 19(2): 304. CrossRef
Combining therapeutic agents to target the immune systems of hepatitis B patients: what do we need to consider?
Shang-Chin Huang, Jia-Horng Kao
Expert Review of Gastroenterology & Hepatology.2025; 19(4): 371. CrossRef
Efficacy of Antiviral Therapy in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase: A Systematic Review and Meta‐Analysis
Yuting Diao, Yueying Zeng, Zhihao Huang, Chunfang You, Kevork M. Peltekian
Canadian Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef
Hepatitis B: Neue therapeutische Ansätze für eine funktionelle Heilung
Markus Cornberg, Ulrike Protzer
Deutsches Ärzteblatt Online.2025;[Epub] CrossRef
Structural optimization of phthalazine derivatives for anti-HBV activities to improve oral bioavailability
Yurong Yang, Fuling Xiao, Jianping Zuo, Li Yang, Youhong Hu, Wuhong Chen
Bioorganic & Medicinal Chemistry.2025; 128: 118259. CrossRef
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies
Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
Hepatology International.2025; 19(4): 704. CrossRef
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure
Ana Verma, Raymond T. Chung
Current Opinion in HIV and AIDS.2025; 20(5): 449. CrossRef
Challenges and advances in clinical cure of chronic hepatitis B
Xu-Ling Liu, Yu-Lang Jiang, Ming-Yu Sun
World Chinese Journal of Digestology.2025; 33(9): 693. CrossRef
Small molecule HBV RNA destabilizing drugs: Drugs of the future or compounds from the past?
Timothy M. Block, Dimitar Gotchev, Yanming Du
Antiviral Research.2025; 244: 106288. CrossRef
Global strategies and actions to eliminate hepatitis B virus infection
Chih-Lin Lin, Jia-Horng Kao
Clinical and Molecular Hepatology.2025; 31(4): 1197. CrossRef
Morphometric and structural dynamic parameters of hepatitis viruses: implications for therapeutic and vaccine failure
Saganuwan Alhaji Saganuwan
Discover Viruses.2025;[Epub] CrossRef
Functional cure of chronic hepatitis B virus infection: current therapeutic regimens
Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao
Hepatoma Research.2025;[Epub] CrossRef

13,680 View
543 Download
20 Web of Science
Crossref

Viral hepatitis

Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”: Mirko Zoncapè, Emmanuel A. Tsochatzis; Clin Mol Hepatol 2025;31(1):e117-e118.
Published online November 11, 2024; DOI: https://doi.org/10.3350/cmh.2024.0994

PDF

5,668 View
26 Download

Hepatitis E as a trigger for acute-on-chronic liver failure: Maria Buti, Juan Carlos Ruiz-Cobo, Rafael Esteban, Mar Riveiro-Barciela; Clin Mol Hepatol 2025;31(Suppl):S196-S204.
Published online November 11, 2024; DOI: https://doi.org/10.3350/cmh.2024.0758

Abstract
PDF

Acute hepatitis E virus (HEV) infection is typically self-limiting and has a favourable prognosis. However, certain populations such as patients with pre-existing chronic liver disease may experience severe manifestations, including progression to acute-on-chronic liver failure (ACLF). Among viral hepatitis types, hepatitis A, E, and B are major causes of ACLF. Active screening and early diagnosis of HEV infection in patients with cirrhosis, especially those who develop ACLF, can improve management and enable timely antiviral therapy. Preventive measures, including HEV vaccination for high-risk groups, could reduce the morbidity and mortality associated with hepatitis E.

Citations

Citations to this article as recorded by

Virus de la hepatitis E: un problema de salud pública emergente
María Teresa Pérez-Gracia, Lara Martínez-Celdrán, Clara Más-Comes
Medicina Clínica.2026; 166(2): 107286. CrossRef
Shellfish as a Potential Source of Hepatitis E Virus: Epidemiological Evidence, Biological Plausibility, and Research Gaps
Hiroaki Okamoto
Viruses.2026; 18(2): 220. CrossRef
Hepatitis E virus: An emerging public health problem
María Teresa Pérez-Gracia, Lara Martínez-Celdrán, Clara Más-Comes
Medicina Clínica (English Edition).2026; 166(2): 107286. CrossRef
Clinical characteristics of hospitalized patients with hepatitis E virus infection in Poland: a multi-centre retrospective study
Anna Parfieniuk-Kowerda, Jerzy Jaroszewicz, Piotr Grabarczyk, Dorota Zarebska-Michaluk, Katarzyna Sikorska, Anna Piekarska, Aleksandra Berkan-Kawinska, Dorota Kozielewicz, Małgorzata Pawlowska, Monika Pazgan-Simon, Barbara Sobala-Szczygiel, Piotr Zielinsk
Advances in Medical Sciences.2026; 71(1): 75. CrossRef
Global Temporal Trends and Projections of Acute Hepatitis E Epidemiology for Adults 65 Years and Older from 1990 to 2021: Global Burden of Disease 2021 Based Study
Shuangshuang Ma, Qingling Wang, Junjie Lin, Yufeng Gao
Tropical Medicine and Infectious Disease.2026; 11(3): 82. CrossRef
Cholinesterase and the association between hepatic steatosis and liver fibrosis in patients with prior hepatitis E
Ziteng Wang, Zhe Yu, Wen An, Herui Wei, Jing Luo, Mengqi Li, Lingling He, Jiali Ma, Fan Xiao, Lijuan Sun, Qi Gao, Hui Zhong, Hongshan Wei
European Journal of Medical Research.2026;[Epub] CrossRef
Hepatitis E Virus Infection as a Trigger of Hepatic Decompensation: A Single‐Center Prospective and Cross‐Sectional Study From Rosario, Argentina
Julián Acosta, Alceo Galimberti, Fernando Bessone, Hugo Tanno, Daniela Gardiol, María Virginia Reggiardo, Ana Laura Cavatorta
Journal of Medical Virology.2026;[Epub] CrossRef
Nationwide Detection and Molecular Characterization of Hepatitis E Virus RNA in Retail Pork Meat in Japan
Masaharu Takahashi, Manri Kawakami, Yukihiro Sato, Tatsunori Nakano, Jun Inoue, Junichi Koyama, Hitoshi Mizuo, Tomoya Koda, Kazumi Yamasaki, Hiroshi Okano, Akio Miyasaka, Shunji Watanabe, Norio Isoda, Tomofumi Takagi, Shinji Fujiwara, Hiroshi Ohnishi, Put
Viruses.2026; 18(6): 621. CrossRef
Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver Cirrhosis
Katja Dinkelborg, Christian Niehaus, Birgit Bremer, Christine Wundes, Anja Tiede, Natalie Petruch, Katja Deterding, Anke R. M. Kraft, Björn Hartleben, Markus Cornberg, Heiner Wedemeyer, Patrick Behrendt, Benjamin Maasoumy
Liver International.2026;[Epub] CrossRef
Efficacy and safety of mesenchymal stem cell therapy in acute on chronic liver failure: a systematic review and meta-analysis of randomized controlled clinical trials
Wenming Lu, Longxiang Yan, Lulu Peng, Xuesong Wang, Xingkun Tang, Jing Du, Jing Lin, Zhengwei Zou, Lincai Li, Junsong Ye, Lin Zhou
Stem Cell Research & Therapy.2025;[Epub] CrossRef
Hepatitis A and E Viruses Are Important Agents of Acute Severe Hepatitis in Asia: A Narrative Review
Reina Sasaki-Tanaka, Tatsuo Kanda, Takeshi Yokoo, Hiroyuki Abe, Kazunao Hayashi, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai
Pathogens.2025; 14(5): 454. CrossRef
The role of bacterial outer membrane vesicles in inflammatory response of acute-on-chronic liver failure
Xiaojing Qin, Shuang Wang, Zhanyao Yan, Ninghui Zhao, Jia Yao
Frontiers in Microbiology.2025;[Epub] CrossRef
Ribavirina como tratamiento de hepatitis E aguda grave sobre hepatopatía crónica: experiencia clínica
Alba Rabadán Mata, María Dolores Antón Conejero, José María Paredes Arquiola
Medicina Clínica.2025; 165(6): 107187. CrossRef
Ribavirin as a treatment for severe acute hepatitis E on chronic liver disease: Clinical experience
Alba Rabadán Mata, María Dolores Antón Conejero, José María Paredes Arquiola
Medicina Clínica (English Edition).2025; 165(6): 107187. CrossRef

8,396 View
198 Download
10 Web of Science
Crossref

Viral hepatitis

Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”: Robert J. Wong; Clin Mol Hepatol 2025;31(2):603-605.
Published online October 29, 2024; DOI: https://doi.org/10.3350/cmh.2024.0929

PDF

Citations

Citations to this article as recorded by

Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TOR
Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin
Clinical and Molecular Hepatology.2025; 31(2): e169. CrossRef

6,432 View
35 Download
1 Web of Science
Crossref

Steatotic liver disease

Bioactive metabolites: A clue to the link between MASLD and CKD?: Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun; Clin Mol Hepatol 2025;31(1):56-73.
Published online October 21, 2024; DOI: https://doi.org/10.3350/cmh.2024.0782

Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the bacterial metabolism of dietary substrates, modification of host molecules (such as bile acids [BAs], trimethylamine-N-oxide, and short-chain fatty acids), or products directly derived from bacteria. Recent studies have provided new insights into the association between MASLD and the risk of developing chronic kidney disease (CKD). Furthermore, alterations in microbiota composition and metabolite profiles, notably altered BAs, have been described in studies investigating the association between MASLD and the risk of CKD. This narrative review discusses alterations of specific classes of metabolites, BAs, fructose, vitamin D, and microbiota composition that may be implicated in the link between MASLD and CKD.

Citations

Citations to this article as recorded by

Radish Green Extract Attenuates Western Diet-Induced Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice
Hye-Bin Lee, Yu Ra Lee, Eunjung Lee, Seong Un Jeong, Jae-Hyun Yoon, Miri Park, Yoonsook Kim, Ho-Young Park
Journal of Agricultural and Food Chemistry.2026; 74(1): 874. CrossRef
Multi-omics reveal the key role of gut microbiota metabolism in adenine-induced chronic kidney disease
Yijing Xin, Hui Ma, Xiang Li, Ruiyang Sun, Luo Fang, Libin Pan
Toxicology and Applied Pharmacology.2026; 509: 117754. CrossRef
Research Progress on the Bile Acid Metabolome in Arteriovenous Fistula Stenosis among Maintenance Hemodialysis Patients
佩张
Advances in Clinical Medicine.2026; 16(03): 2204. CrossRef
Creatinine clearance rate predicts all-cause and cardiovascular mortality in patients with MASLD: a Shanghai cohort study
Yingqi Hou, Yanqiu Huang, Chenghao Zhang, Wen Gu, Yadan Xu, Shuli Li, Jugang Wu, Jibin Liu, Honglin Liu
Frontiers in Medicine.2026;[Epub] CrossRef
Plasma proteome profiling identifies XPNPEP3 as a novel biomarker associated with metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus
Hua Ji, Yating Lu, Yichang Liu, Yinguang Jia, Jie Liu, Datong Deng, Mingwei Chen
Annals of Medicine.2026;[Epub] CrossRef
Loss of immunometabolic adaptability in MASH: gut-derived signals drive macrophage reprogramming and fibrosis
Yan Li, Yuyuan Hu, Yuan He, Yuhang Yang, Dingwen Xue, Erkui Xue, Jinghan Jia, Wei Zhang, Jinxi Wang
Frontiers in Immunology.2026;[Epub] CrossRef
Ferroptosis in MASLD: From molecular mechanisms to therapeutic opportunities
Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Wei Xie, Qin-Fen Chen, Yuxing Dong, Fudi Wang, Daolin Tang, Ming-Hua Zheng
Med.2026; : 101099. CrossRef
Classification of intestinal inflammation driven by gut microbiota metabolites: a new paradigm for precision treatment of cardiovascular diseases
Dahua Zhao, Yanjun Cui, Zhen Hua
Frontiers in Microbiology.2026;[Epub] CrossRef
Bile Acids and the Gut–X Axis: TCM-Mediated Systemic Protection and Therapeutic Opportunities for Multi-Organ Diseases
Jialu He, Linjie Qin, Xian Sun
Metabolites.2026; 16(6): 366. CrossRef
Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges
Dario Piatto, Delia De Biasio, Francesco Giustino Cesaro, Gianmario Forcina, Vittoria Frattolillo, Antonio Colucci, Fabio Lamberti, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa
Journal of Clinical Medicine.2025; 14(11): 3911. CrossRef
Altered mitochondrial function: a clue therapeutic strategies between metabolic dysfunction-associated steatotic liver disease and chronic kidney disease?
Jiang Bai, Lijuan Zhang, Letian He, Yun Zhou
Frontiers in Nutrition.2025;[Epub] CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review
Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi
Nutrients.2025; 17(13): 2211. CrossRef
Quyu Huazhuo Decoction alleviates non-Alcoholic steatohepatitis via remodeling the gut microbiota and regulating bile acid and short-chain fatty acid metabolism
Lu Lu, Chengting Wu, Juhong Jia, Yuanqin Du, Yujiao Peng, Hongna Huang, Jingjing Huang, Yaobin Nong
Journal of Chromatography B.2025; 1267: 124784. CrossRef
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management
Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano
Exploration of Medicine.2025;[Epub] CrossRef
Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications
Wenhua Bai, Zheng Zhu
Frontiers in Endocrinology.2025;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis are Associated with Advanced Cardiovascular-Kidney-Metabolic Syndrome in Chinese and US Populations
Shidi Hu, Dongmei Wang, Qingtao Yu, Zhi Chen, Weiguo Lu, Yuan Meng, Xuetao Peng, Lan Liu, Heng Wan, Jie Shen
Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 4699. CrossRef

10,499 View
250 Download
13 Web of Science
Crossref

Viral hepatitis

Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs: Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau; Clin Mol Hepatol 2025;31(1):e19-e20.
Published online October 17, 2024; DOI: https://doi.org/10.3350/cmh.2024.0906

PDF

6,645 View
42 Download

Viral hepatitis

Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial: Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, Chieh-Chang Chen, Teng-Yu Lee, Ming-Jong Bair, Jyh-Jou Chen, Yen-Tsung Huang, I-Wei Chang, Chi-Yang Chang, Chun-Ying Wu, Ming-Shiang Wu, Lein-Ray Mo, Jaw-Town Lin; Clin Mol Hepatol 2025;31(1):213-226.
Published online October 17, 2024; DOI: https://doi.org/10.3350/cmh.2024.0640

Background/Aims
Treatment indications for patients with chronic hepatitis B (CHB) remain contentious, particularly for patients with mild alanine aminotransferase (ALT) elevation. We aimed to evaluate treatment effects in this patient population.
Methods
This rollover study extended a placebo-controlled trial that enrolled non-cirrhotic patients with CHB and ALT levels below two times the upper limit of normal. Following 3 years of randomized intervention with either tenofovir disoproxil fumarate (TDF) or placebo, participants were rolled over to open-label TDF for 3 years. Liver biopsies were performed before and after the treatment to evaluate histopathological changes. Virological, biochemical, and serological outcomes were also assessed (NCT02463019).
Results
Of 146 enrolled patients (median age 47 years, 80.8% male), 123 completed the study with paired biopsies. Overall, the Ishak fibrosis score decreased in 74 (60.2%), remained unchanged in 32 (26.0%), and increased in 17 (13.8%) patients (p<0.0001). The Knodell necroinflammation score decreased in 58 (47.2%), remained unchanged in 29 (23.6%), and increased in 36 (29.3%) patients (p=0.0038). The proportion of patients with an Ishak score ≥ 3 significantly decreased from 26.8% (n=33) to 9.8% (n=12) (p=0.0002). Histological improvements were more pronounced in patients switching from placebo. Virological and biochemical outcomes also improved in placebo switchers and remained stable in patients who continued TDF. However, serum HBsAg levels did not change and no patient cleared HBsAg.
Conclusions
In CHB patients with minimally raised ALT, favorable histopathological, biochemical, and virological outcomes were observed following 3-year TDF treatment, for both treatment-naïve patients and those already on therapy.

8,075 View
204 Download
5 Web of Science

Viral hepatitis

Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”: Young-Joo Jin, Seung Up Kim; Clin Mol Hepatol 2025;31(1):e55-e57.
Published online October 7, 2024; DOI: https://doi.org/10.3350/cmh.2024.0846

PDF

Citations

Citations to this article as recorded by

Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
Mirko Zoncapè, Emmanuel A. Tsochatzis
Clinical and Molecular Hepatology.2025; 31(1): e117. CrossRef

5,776 View
32 Download
1 Web of Science
Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Sinusoidal communication in chronic liver disease: Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, Pablo Alfaro-Retamero, Sergi Guixé-Muntet, Jordi Gracia-Sancho; Clin Mol Hepatol 2025;31(1):32-55.
Published online October 2, 2024; DOI: https://doi.org/10.3350/cmh.2024.0734

Abstract
PDF

The liver sinusoid, mainly composed of liver sinusoidal endothelial cells, hepatic macrophages and hepatic stellate cells, shapes the hepatic vasculature and is key to maintaining liver homeostasis and function. During chronic liver disease (CLD), the function of sinusoidal cells is impaired, being directly involved in the progression of liver fibrosis, cirrhosis, and main clinical complications including portal hypertension and hepatocellular carcinoma. In addition to their roles in liver diseases pathobiology, sinusoidal cells’ paracrine communication or cross-talk is being studied as a mechanism of disease but also as a remarkable target for treatment. The aim of this review is to gather current knowledge of intercellular signalling in the hepatic sinusoid during the progression of liver disease. We summarise studies developed in pre-clinical models of CLD, especially emphasizing those pathways characterized in human-based clinically relevant models. Finally, we describe pharmacological treatments targeting sinusoidal communication as promising options to treat CLD and its clinical complications.

Citations

Citations to this article as recorded by

Hepatic Fibrosis and Liver Cancer
Aina Anton, Scott L. Friedman, Bruno Cogliati
Seminars in Liver Disease.2026; 46(01): 031. CrossRef
Regression of fibrosis and portal hypertension in chronic liver disease: Endothelial perspectives and clinical implications
Yuly P Mendoza, Raül Pastó, Sonia E Selicean, Jordi Gracia-Sancho
Annals of Hepatology.2026; 31(1): 102174. CrossRef
LSEC-derived CXCL9 orchestrates immune recruitment and hepatocyte reprogramming in liver fibrosis
Jing Li, Qiannan Di, Xiujuan Zhou, Mengling Chang, Wei Chen
Acta Biochimica et Biophysica Sinica.2026;[Epub] CrossRef
Nodular Transformation–driven Circulatory Remodeling in Biliary Atresia–induced Pediatric Biliary Cirrhosis: A Three-dimensional Phase-Contrast CT Rendering
Bei-Ning Qi, Xin-Yan Zhao, Wen-Juan Lv, Shan Shan, Xian-qin Du, Jian-Bo Jian, Chun-Hong Hu
Radiology.2026;[Epub] CrossRef
Sinusoidal cell–derived biomarker scores predict diagnosis and prognosis in chronic liver disease
Sergi Guixé-Muntet, Anabel Fernández-Iglesias, David Lopez, Emilio Tonina, Yiliam Fundora, Anna Zagorska, Jordi Gracia-Sancho
BMC Medicine.2026;[Epub] CrossRef
P7C3 alleviates hepatic fibrosis via targeting eIF4A1-mediated protein translation and autophagy in hepatic stellate cells
Ailing Liang, Ling Yao, Yuanyuan Liu, Honglin He, Yao Lei, Yunheng Yang, Jun Liu, Jiamei Yu, Weiguo Cao, Zhiwei Chen
Archives of Pharmacal Research.2026; 49(2): 262. CrossRef
Clinical challenges and transjugular intrahepatic portosystemic shunt strategies for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: an Asian perspective
Tan-Yang Zhou, Hong-Liang Wang, Zhi-Cheng Jin, Bin Xiong, Ji Hoon Shin
Korean Journal of Interventional Radiology.2026; 31(1): 24. CrossRef
Kupffer cells and monocyte-derived macrophages in the pathogenesis and treatment of hepatocellular carcinoma
Argyro Voumvouraki, Ioannis Tsomidis, Elias Kouroumalis
Hepatoma Research.2026;[Epub] CrossRef
Extracellular Vesicles in Hepatic Pathogenesis: From Biogenesis to Biomarkers
Tamer A. Addissouky
Archives of Molecular Biology and Genetics.2026; 5(1): 10. CrossRef
Vasomics of the liver
Chengyan Wang, Eric Felli, Jonathan Andrew Fallowfield, Christoph Frank Dietrich, Don Rockey, Jürgen Hennig, Gao-Jun Teng, Jordi Gracia-Sancho, Xiaolong Qi
Gut.2025; 74(6): 1008. CrossRef
Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells
Enis Kostallari, Robert F. Schwabe, Adrien Guillot
Cellular & Molecular Immunology.2025; 22(10): 1205. CrossRef
Myeloid cells in chronic liver inflammation
Dimitrios Patseas, Ahmed El-Masry, Zuobin Liu, Prakash Ramachandran, Evangelos Triantafyllou
Cellular & Molecular Immunology.2025; 22(10): 1237. CrossRef
Toll-like receptor 4-mediated inflammatory stimulation in Kupffer cell enhances arsenite-induced liver fibrosis by triggering hepatic stellate cell activation
Qian Song, Meitong Zhou, Rui He, Heng Diao, Lili Fan, Chenglong Tu, Xiong Chen, Dapeng Wang
Ecotoxicology and Environmental Safety.2025; 303: 118903. CrossRef
The pathophysiological role of portal hypertension in metabolic dysfunction–associated steatotic liver disease
Søren Møller, Sannia M.S. Sjöstedt, Lise Hobolth, Christian Mortensen, Nina Kimer
Hepatology Communications.2025;[Epub] CrossRef
Hepatocyte-derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p-pyroptosis axis
Laia Abad-Jordà, María Andrés-Rozas, Ana Martínez-Alcocer, Jessica Aspas, Yiliam Fundora, Sonia Fernández-Veledo, Carmen Peralta, Sergi Guixé-Muntet, Anabel Fernández-Iglesias, Jordi Gracia-Sancho
Hepatology.2025;[Epub] CrossRef

12,519 View
321 Download
12 Web of Science
Crossref

Liver Transplantation

Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation: Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, Pil Soo Sung, Seung Kew Yoon, Jeong Won Jang, Jong Young Choi; Clin Mol Hepatol 2025;31(1):131-146.
Published online October 2, 2024; DOI: https://doi.org/10.3350/cmh.2024.0451

Background/Aims
This study aimed to identify the risk factors for chronic kidney disease (CKD) and end-stage renal disease (ESRD) following liver transplantation (LT), with a specific focus on tacrolimus levels and intrapatient variability (IPV).
Methods
Among the 1,076 patients who underwent LT between 2000 and 2018, 952 were included in the analysis. The tacrolimus doses and levels were recorded every 3 months, and the IPV was calculated using the coefficient of variability. The cumulative incidence rates of CKD and ESRD were calculated based on baseline kidney function at the time of LT. The impact of tacrolimus levels and their IPV on the development of CKD and ESRD was evaluated, and the significant risk factors were identified.
Results
Within a median follow-up of 97.3 months, the 5-year cumulative incidence rates of CKD (0.58 vs. 0.24) and ESRD (0.07 vs. 0.01) were significantly higher in the acute kidney injury group than in the normal glomerular filtration rate (GFR) group. In the normal GFR group, the tacrolimus levels were identified as a risk factor for CKD, with a level of ≤4.5 ng/mL suggested as optimal for minimizing the risk of CKD. Furthermore, the IPV of tacrolimus levels and doses emerged as a significant risk factor for CKD development in both groups (p<0.05), with tenofovir disoproxil fumarate also being a risk factor in HBV-infected patients. The IPV of tacrolimus levels was also a significant factor in ESRD development (p<0.05).
Conclusions
This study elucidated the optimal tacrolimus trough level and highlighted the impact of IPV on the CKD and ESRD development post-LT.

Citations

Citations to this article as recorded by

Schisandrin B alleviates liver allograft rejection by stabilizing ACOD1 in Kupffer cells to potentiate itaconate-NRF2-mediated suppression of CD8+ T cell chemotaxis
Yihua Wang, Dadi Peng, Dengliang Lei, Liqing Jiang, Song Xiang, Qiuying Li, Hong Zhang, Zhongjun Wu, Chao Yu, Tengxiang Chen
Phytomedicine.2026; 154: 158031. CrossRef
Enhanced ocular delivery of tacrolimus via cationic nanoliposomes: Mitigating inflammation and rebalancing Th17/Treg responses in dry eye disease
Lirui Liu, Dan Chen, Siting Sheng, Xueqi Lin, Huiling Zhao, Chujun Liu, Xiang Chen, Yang Ye, Wen Xu
Materials Today Bio.2026; 38: 103248. CrossRef
Rethinking chronic kidney disease risk after liver transplantation
Concetto Sessa, Guido Gembillo, Walter Morale
World Journal of Transplantation.2026;[Epub] CrossRef
Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development foll
Jongman Kim
Clinical and Molecular Hepatology.2025; 31(2): 589. CrossRef
Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Soon Kyu Lee, Jong Young Choi
Clinical and Molecular Hepatology.2025; 31(2): e212. CrossRef
Clinical significance and gene prediction of a novel classification system based on tacrolimus concentration-to-dose ratio in the early post-liver transplant period
Junwei Fan, Peihao Wen, Liyun Yuan, Yan Xia, Shijie Hu, Xiaoqing Zhang, Zhihai Peng
Frontiers in Pharmacology.2025;[Epub] CrossRef
Chronic kidney disease at one year after liver transplantation: Role of changes in immunosuppression over three decades
Alejandro Muñoz-Serrano, María Jesús Citores, Andrea Gutiérrez-Villanueva, Víctor Moreno-Torres, Jorge V López-Ibor, Natalia Vicente, Valentín Cuervas-Mons
World Journal of Transplantation.2025;[Epub] CrossRef

13,622 View
239 Download
7 Web of Science
Crossref

Viral hepatitis

The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”: Mirko Zoncapè, Emmanuel A. Tsochatzis; Clin Mol Hepatol 2025;31(1):268-274.
Published online September 24, 2024; DOI: https://doi.org/10.3350/cmh.2024.0817

PDF

Citations

Citations to this article as recorded by

Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
Mirko Zoncapè, Emmanuel A. Tsochatzis
Clinical and Molecular Hepatology.2025; 31(1): e117. CrossRef
Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
Young-Joo Jin, Seung Up Kim
Clinical and Molecular Hepatology.2025; 31(1): e55. CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef

7,871 View
62 Download
3 Web of Science
Crossref

Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis”: Ho Soo Chun, Minjong Lee; Clin Mol Hepatol 2025;31(1):261-263.
Published online September 20, 2024; DOI: https://doi.org/10.3350/cmh.2024.0795

PDF

Citations

Citations to this article as recorded by

Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment
Ina Bergheim, Jean Francois Cadranel, Jianguo Chen, Wenxing Ding, Robert Eferl, Carmen Garcia-Ruiz, Hartmut Jaeschke, Firouzeh Kazerouni, Amedeo Lonardo, Derek A. Mann, Nahum Méndez-Sánchez, Camelia Mokhtari, Han Moshage, Chiara Raggi, Pavel Strnad, Oren
Exploration of Digestive Diseases.2026;[Epub] CrossRef

8,761 View
65 Download
Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”: Chuan Liu, Ling Yang, Hong You, Gao-Jun Teng, Xiaolong Qi; Clin Mol Hepatol 2025;31(2):e155-e157.
Published online August 30, 2024; DOI: https://doi.org/10.3350/cmh.2024.0723

PDF

6,713 View
65 Download

Liver fibrosis, cirrhosis, and portal hypertension

KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease: Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim, on behalf of The Korean Association for the Study of the Liver (KASL); Clin Mol Hepatol 2024;30(Suppl):S5-S105.
Published online August 19, 2024; DOI: https://doi.org/10.3350/cmh.2024.0506

Citations

Citations to this article as recorded by

Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Haiyu Wang, Jinjun Chen
Clinical and Molecular Hepatology.2026; 32(1): e58. CrossRef
Refining portal hypertension assessment: The clinical significance of spleen stiffness measurement in the Baveno VII Era: Editorial on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Do Seon Song
Clinical and Molecular Hepatology.2026; 32(1): 400. CrossRef
Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement
Joseph Rabbat, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jérôme Boursier, José Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Rocio Gallego-Durán,
Clinical and Molecular Hepatology.2026; 32(1): 289. CrossRef
Non-invasive Risk-based Surveillance Strategy for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease
Ji Won Han
The Korean Journal of Gastroenterology.2026; 86(1): 62. CrossRef
2025 KASL clinical practice guidelines for management of hepatitis C
Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, Jung Gil Park, Do Seon Song, Eun Ju Cho, Chang Hun Lee, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jung
Clinical and Molecular Hepatology.2026; 32(1): 1. CrossRef
Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes
Gi-Ae Kim, Heejoon Jang, Moon Young Kim, Jeong Hwan Park, Jung Gil Park, Eun-Young Cho, Jae Yoon Jeong, Seogsong Jeong, Seul Ki Han, Heesu Kwon, Youngae Jung, Geum-Sook Hwang, Yu Rim Lee, Soo Young Park, Sang Gyune Kim, Won Kim
Gastroenterology.2026; 170(7): 1571. CrossRef
PNPLA3 I148M is unrelated to HCC occurrence but associates with poorer tumor differentiation in Korean MASLD: a prospective cohort of 562 patients
Jaejun Lee, Dong Yeop Lee, Jung Hoon Cha, Hee Sun Cho, Keungmo Yang, Hyun Yang, Mi Young Byun, Seok Keun Cho, Seong Wook Yang, Si Hyun Bae, Pil Soo Sung
Journal of Liver Cancer.2026; 26(1): 147. CrossRef
Optimal screening criteria for metabolic dysfunction-associated steatotic liver disease with fibrosis
Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
Annals of Hepatology.2026; 31(2): 102199. CrossRef
Diagnostic Value of MR Elastography and MRI‐Proton Density Fat Fraction in Cirrhosis Based on Explant Liver Histology
Eun‐Ki Min, Seung‐seob Kim, Byungsoo Ahn, Deok‐Gie Kim, Dong Jin Joo, Sang Hoon Ahn, Seung Up Kim, Jae Geun Lee
Journal of Gastroenterology and Hepatology.2026; 41(4): 1323. CrossRef
Systematic Review: Imaging‐Based Morphological Criteria for Liver Cirrhosis—A Call to Standardise
Mei Chin Lim, Ethan Joo Wei Quek, Talia Yi Hui Chan, Margaret Teng, Cheng Han Ng, Mirudhula Gnanavelou, Vincent L. Chen, Jonathan A. Fallowfield, Huimiao Zhang, Mazen Noureddin, Donghyun Ko, Benjamin Nah, Hirokazu Takahashi, Mohammad Shadab Siddiqui, Jimm
Alimentary Pharmacology & Therapeutics.2026; 63(9): 1201. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach
Beom Kyung Kim
The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
The MASLD Journey in the General Population: Linkage‐to‐Care and Patient‐Reported Uptake of Fibrosis Risk Assessment
Joo Hyun Oh, Jun‐Hyuk Lee, Sang Bong Ahn, Eunjoo Kwon, Eileen L. Yoon, Hyo Young Lee, Seon Cho, Dae Won Jun
Liver International.2026;[Epub] CrossRef
Rethinking first-line screening in MASLD beyond the limitations of Fibrosis-4 index: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”
Han Ah Lee, Young Youn Cho, Hyung Joon Kim
Clinical and Molecular Hepatology.2026; 32(2): 921. CrossRef
AI Framework Integrated with InN Gas Sensing to Distinguish Sedentary Metabolic Fingerprints from Chronic Liver Disease
Tsung Ming Chao, Rakesh Kumar Patnaik, Yu Chen Lin, Ming-Chih Ho, Zhe Liang Yeh
AI Sensors.2026; 2(2): 6. CrossRef
Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort
Seogsong Jeong, Gi‐Ae Kim, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Keon Wook Kang, Hwamin Lee, Won Kim
Alimentary Pharmacology & Therapeutics.2026;[Epub] CrossRef
Combined Associations of Lead and Arsenic Species with Liver Dysfunction and Hepatic Fibrosis Among Young Adults in Taiwan
Kai-Wei Liao, Chih-Wen Wang, Wei-Lun Hung, Ya-Ling Chen, Yee-How Say, Yang-Ching Chen, Wei-Shan Chin
Exposure and Health.2026;[Epub] CrossRef
Inflammatory activity stratification improves liver stiffness diagnosis of fibrosis in autoimmune hepatitis
Yan Huang, Delin Liu, Yunjiang Li, Xu Zhang, Yu Tang
Frontiers in Immunology.2026;[Epub] CrossRef
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
Hee Yeon Kim, Miyoung Choi, Dae Won Jun
Clinical and Molecular Hepatology.2025; 31(1): e48. CrossRef
Non-Invasive Liver Fibrosis Test Using Shear Wave Elastography
Ji Won Han
The Korean Journal of Medicine.2025; 100(1): 26. CrossRef
Influence of Sex in the Development of Liver Diseases
Jie-Wen Zhang, Nan Zhang, Yi Lyu, Xu-Feng Zhang
Seminars in Liver Disease.2025; 45(01): 015. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang
Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
Noninvasive identification of metabolic dysfunction–associated steatohepatitis (INFORM MASH): a retrospective cohort and disease modeling study
G. Craig Wood, Anthony Hoovler, Rakesh Luthra, Christopher D. Still, Hamzah Shariff, Matthew Still, Jonathan Hayes, Peter Benotti, Chioma Uzoigwe
Expert Review of Gastroenterology & Hepatology.2025; 19(4): 427. CrossRef
Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liv
Ji Won Han, Dae Won Jun
Clinical and Molecular Hepatology.2025; 31(2): e152. CrossRef
The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study
Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang
BMC Gastroenterology.2025;[Epub] CrossRef
Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C
Beom Kyung Kim
Journal of Gastroenterology and Hepatology.2025; 40(8): 1855. CrossRef
Novel Insights into Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C Patients
Guanlan Liu, Li Liu, Xing Yang, Qihao Wang, Mingqin Qian
Journal of Clinical and Experimental Hepatology.2025; 15(6): 102610. CrossRef
A Case Report of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Improved Cardiometabolic Risk Factors Following Treatment with Saenggangunbi-tang
Eun Kyung Lee, Min Jeong Park, Youngchul Kim, Jang-Hoon Lee
The Journal of Internal Korean Medicine.2025; 46(2): 303. CrossRef
Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
Clinical and Molecular Hepatology.2025; 31(3): 1018. CrossRef
Performance of APRI and FIB-4 Scores Compared to FibroScan: A Cross-Sectional Study in a Black Sub-Saharan African Population
Jean-Bonny Nsumbu, Jean-Robert Makulo, Trésor Mutombo Tshiswaka, Christian Kisoka Lusunsi, Charles Nlombi Mbendi
Hepatic Medicine: Evidence and Research.2025; Volume 17: 27. CrossRef
Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis
Toshikazu Kohira, Satoshi Oeda, Erina Eto, Yoshihito Kubotsu, Misa Norita, Kaori Inoue, Nagisa Hara, Shotaro Noge, Kenichi Tanaka, Shigenobu Yoshimura, Noriko Oza, Keizo Anzai, Yuichiro Eguchi, Cheng Han Ng, Daniel Q. Huang, Mark D. Muthiah, Atsushi Kawag
Scientific Reports.2025;[Epub] CrossRef
Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study
Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim
Medicina.2025; 61(9): 1601. CrossRef
Comment on ‘Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank’ by T. S. Lim et al.—Authors' Reply
Tae Seop Lim, Sujin Kwon, Sung A Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis
Brian Lee, Ussama Ghumman, Lisa D. Pedicone, Andres Gomez Aldana, Eric Lawitz
Clinical and Molecular Hepatology.2025; 31(4): 1167. CrossRef
Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis
Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li
European Journal of Medical Research.2025;[Epub] CrossRef
Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review
Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva
Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1299. CrossRef
Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-male-albumin-bilirubin-platelet (aMAP) and Liver Stiffness Assessed by Vibration-controlled Transient Elastography
Hye Yeon Chon, Hyung Joon Yim, Seok-Jae Heo, Su Jong Yu, Ja Kyung Kim, Sang Hoon Ahn, Grace Lai-Hung Wong, Jimmy Che-To Lai, Terry Cheuk-Fung Yip, Sang Gyune Kim, Yeon Seok Seo, Seung Up Kim
Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
A Novel Deep Learning Framework for Liver Fibrosis Staging and Etiology Diagnosis Using Integrated Liver–Spleen Elastography
Kai Yang, Fei Chen, Aiping Tian, Long Deng, Xiaorong Mao
Diagnostics.2025; 15(23): 2986. CrossRef
Shear-Wave Elastography: Principles, Techniques, and Clinical Considerations
Jae Seung Lee
Clinical Ultrasound.2025; 10(2): 53. CrossRef
Vibration-Controlled Transient Elastography in Chronic Liver Disease: Current Research Insights
Ho Soo Chun
Clinical Ultrasound.2025; 10(2): 69. CrossRef
Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease
Jung Hwan Yu
The Korean Journal of Medicine.2024; 99(5): 232. CrossRef
Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography
Mi Na Kim
The Korean Journal of Gastroenterology.2024; 84(5): 201. CrossRef
Non-Invasive Test for Assessment of Liver Fibrosis in Chronic Hepatitis B
Ye Ji Jun, Minjong Lee, Ho Soo Chun, Tae Hun Kim
The Korean Journal of Gastroenterology.2024; 84(5): 206. CrossRef
Serological Markers to Assess Liver Fibrosis and Their Roles
Beom Kyung Kim
The Korean Journal of Gastroenterology.2024; 84(5): 195. CrossRef
Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography
Han Ah Lee
Clinical Ultrasound.2024; 9(2): 70. CrossRef

21,466 View
375 Download
42 Web of Science
Crossref

Page Path

"Chronic"

Article category

Keywords

Publication year

Article category

Keywords

Publication Year

Funded articles

"Chronic"

Special Issue

Review Article

Correspondence

Review

Editorials

Correspondence

Letter to the Editor

Editorial

Review

Letter to the Editor

Original Article

Correspondence

Reply to Correspondence

Correspondence

Reply to Correspondence

Correspondences

Research Letter

Editorial

Correspondence

Editorial

Original Article

Review

Original Article

Correspondences

Liver Transplantation

Editorial

Correspondence

Liver Transplantation

Original Articles

Editorial

Liver Transplantation

Review

Viral hepatitis

Letter to the Editor

Liver Transplantation

Correspondence

Viral hepatitis

Letter to the Editor

Viral hepatitis

Review

Viral hepatitis

Reply to Correspondence

Viral hepatitis

Review

Editorial

Viral hepatitis

Review

Steatotic liver disease

Letter to the Editor

Viral hepatitis

Original Article

Viral hepatitis

Correspondence

Viral hepatitis

Review

Liver fibrosis, cirrhosis, and portal hypertension

Original Article

Liver Transplantation

Editorials

Viral hepatitis

Correspondence

Liver fibrosis, cirrhosis, and portal hypertension

Liver fibrosis, cirrhosis, and portal hypertension

ABOUT

BROWSE ARTICLES

FOR CONTRIBUTORS